T-cell co-stimulation in combination with targeting FAK drives enhanced anti-tumor immunity

Focal Adhesion Kinase (FAK) inhibitors are currently undergoing clinical testing in combination with anti-PD-1 immune checkpoint inhibitors. However, which patients are most likely to benefit from FAK inhibitors, and what the optimal FAK/immunotherapy combinations are, is currently unknown. We ident...

Descripción completa

Detalles Bibliográficos
Autores principales: Canel, Marta, Taggart, David, Sims, Andrew H, Lonergan, David W, Waizenegger, Irene C, Serrels, Alan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: eLife Sciences Publications, Ltd 2020
Materias:
Cancer Biology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6974352/
https://www.ncbi.nlm.nih.gov/pubmed/31959281
http://dx.doi.org/10.7554/eLife.48092

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6974352/
https://www.ncbi.nlm.nih.gov/pubmed/31959281
http://dx.doi.org/10.7554/eLife.48092

Ejemplares similares